Systemic lupus erythematosus. Epidemiology, pathophysiology, manifestations, and management.

Dental Clinics of North America

Volumn 57, Issue 4, 2013, Pages 631-655

  Fortuna, Giulio ^a   Brennan, Michael T ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Epidemiology; Pathophysiology; Systemic lupus erythematous; Treatment

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

DIAGNOSIS; EPIDEMIOLOGY; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

DIAGNOSIS; EPIDEMIOLOGY; PATHOPHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOUS; TREATMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84883783290     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cden.2013.06.003     Document Type: Review

References (149)

1. Blotzer J.W. Systemic lupus erythematosus I: historical aspects. Md State Med J 1983, 32:439-441.
2. Smith C.D., Cyr M. The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am 1988, 14:1-14.
3. Kaposi M.H. Neue Beitrage zur Keantiss des lupus erythematosus. Arch Dermatol Syphilol 1872, 4:36.
4. Olser W. On the visceral manifestations of the erythema group of skin diseases [Third Paper.] 1904. Am J Med Sci 2009, 338:396-408.
5. Jadassohn J. Lupus erythematodes. Handbach der Hautkrakheiten 1904, 298-404. Alfred Holder, Wien. F. Mracek (Ed.).
6. Hargraves M.M., Richmond H., Morton R. Presentation of two bone marrow elements; the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin 1948, 23:25-28.
7. Moore J.E., Lutz W.B. The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors. JChronic Dis 1955, 1:297-316.
8. Friou G.J. Clinical application of lupus serum-Nucleoprotein reaction using the fluorescent antibody technique. JClin Invest 1957, 36:890.
9. Deicher H.R., Holman H.R., Kunkel H.G. The precipitin reaction between DNA and a serum factor in systemic lupus erythematosus. JExp Med 1959, 109:97-114.
10. Tan E.M., Kunkel H.G. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. JImmunol 1966, 96:464-471.
11. Bielschowsky M., Helyer B.J., Howie J.B. Spontaneous hemolytic anemia in mice of the NZB/BL strain. Proc Univ Otago Med Sch 1959, 37:9.
12. Arnett F.C., Shulman L.E. Studies in familial systemic lupus erythematosus. Medicine (Baltimore) 1976, 55:313-322.
13. Hochberg M.C. The application of genetic epidemiology to systemic lupus erythematosus. JRheumatol 1987, 14:867-869.
14. Mok C.C. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2010, 15:53-70.
15. Touma Z., Urowitz M.B., Gladman D.D. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. Expert Opin Biol Ther 2013, 13(5):723-737.
16. Askanase A., Shum K., Mitnick H. Systemic lupus erythematosus: an overview. Soc Work Health Care 2012, 51:576-586.
17. Borchers A.T., Naguwa S.M., Shoenfeld Y., et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9:A277-A287.
18. Laustrup H., Voss A., Green A., et al. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol 2009, 38:128-132.
19. Vilar M.J., Sato E.I. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 2002, 11:528-532.
20. Chakravarty E.F., Bush T.M., Manzi S., et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007, 56:2092-2094.
21. Johnson A.E., Gordon C., Palmer R.G., et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995, 38:551-558.
22. Hopkinson N.D., Doherty M., Powell R.J. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis 1994, 53:675-680.
23. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318.
24. McCarty D.J., Manzi S., Medsger T.A., et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995, 38:1260-1270.
25. Osio-Salido E., Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010, 19:1365-1373.
26. Bae S.C., Fraser P., Liang M.H. The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis". Arthritis Rheum 1998, 41:2091-2099.
27. Mok C.C., To C.H., Ho L.Y., et al. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. JRheumatol 2008, 35:1978-1982.
28. Villamin C.A., Navarra S.V. Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. Mod Rheumatol 2008, 18:161-164.
29. Al Arfaj A.S., Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009, 18:465-473.
30. Borchers A.T., Keen C.L., Shoenfeld Y., et al. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004, 3:423-453.
31. Urowitz M.B., Gladman D.D., Tom B.D., et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. JRheumatol 2008, 35:2152-2158.
32. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
33. Kasitanon N., Magder L.S., Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006, 85:147-156.
34. Pons-Estel B.A., Catoggio L.J., Cardiel M.H., et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 2004, 83:1-17.
35. Alamanos Y., Voulgari P.V., Siozos C., et al. Epidemiology of systemic lupus erythematosus in northwest Greece 1982-2001. JRheumatol 2003, 30:731-735.
36. Houman M.H., Smiti-Khanfir M., Ben G., et al. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 2004, 13:204-211.
37. Rabbani M.A., Habib H.B., Islam M., et al. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 2009, 18:848-855.
38. Wadee S., Tikly M., Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 2007, 46:1487-1491.
39. Peschken C.A., Esdaile J.M. Systemic lupus erythematosus in North American Indians: a population based study. JRheumatol 2000, 27:1884-1891.
40. Malaviya A.N., Chandrasekaran A.N., Kumar A., et al. Systemic lupus erythematosus in India. Lupus 1997, 6:690-700.
41. Molina J.F., Molina J., Garcia C., et al. Ethnic differences in the clinical expression of systemic lupus erythematosus: a comparative study between African-Americans and Latin Americans. Lupus 1997, 6:63-67.
42. Arcon-Segovia D., Arcon-Riquelme M.E., Cardiel M.H., et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005, 52:1138-1147.
43. Al-Maini M.H., El-Ageb E.M., Al-Wahaibi S.S., et al. Demographic, autoimmune, and clinical profiles of patients with systemic lupus erythematosus in Oman. Rheumatol Int 2003, 23:186-191.
44. Graham R.R., Hom G., Ortmann W., et al. Review of recent genome-wide association scans in lupus. JIntern Med 2009, 265:680-688.
45. Moser K.L., Kelly J.A., Lessard C.J., et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373-379.
46. Rhodes B., Vyse T.J. The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology (Oxford) 2008, 47:1603-1611.
47. Reveille J.D., Moulds J.M., Ahn C., et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998, 41:1161-1172.
48. Castano-Rodriguez N., Diaz-Gallo L.M., Pineda-Tamayo R., et al. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev 2008, 7:322-330.
49. Galeazzi M., Sebastiani G.D., Morozzi G., et al. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore) 2002, 81:169-178.
50. Ushiyama O., Ushiyama K., Koarada S., et al. Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2000, 59:705-708.
51. Taylor K.E., Remmers E.F., Lee A.T., et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008, 4:e1000084.
52. Svenungsson E., Gustafsson J., Leonard D., et al. ASTAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010, 69:834-840.
53. Lazarus M., Hajeer A.H., Turner D., et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. JRheumatol 1997, 24:2314-2317.
54. Yang Y., Chung E.K., Wu Y.L., et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007, 80:1037-1054.
55. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. JAutoimmun 2009, 33:3-11.
56. Shiozawa S. Cause of systemic lupus erythematosus: a novel self-organized criticality theory of autoimmunity. Expert Rev Clin Immunol 2011, 7:715-717.
57. Tsumiyama K., Miyazaki Y., Shiozawa S. Self-organized criticality theory of autoimmunity. PLoS One 2009, 4:e8382.
58. Choi J., Kim S.T., Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 2012, 24:651-657.
59. Teichmann L.L., Ols M.L., Kashgarian M., et al. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33:967-978.
60. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
61. Lande R., Ganguly D., Facchinetti V., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19.
62. Garcia-Romo G.S., Caielli S., Vega B., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
63. Cappione A., Anolik J.H., Pugh-Bernard A., et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. JClin Invest 2005, 115:3205-3216.
64. Wardemann H., Nussenzweig M.C. B-cell self-tolerance in humans. Adv Immunol 2007, 95:83-110.
65. Jenks S.A., Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009, 8:209-213.
66. Anders H.J. AToll for lupus. Lupus 2005, 14:417-422.
67. Liu Z., Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011, 32:388-394.
68. Moulton V.R., Tsokos G.C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:207.
69. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
70. Linterman M.A., Rigby R.J., Wong R.K., et al. Follicular helper T cells are required for systemic autoimmunity. JExp Med 2009, 206:561-576.
71. Simpson N., Gatenby P.A., Wilson A., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 62:234-244.
72. Grammer A.C., Slota R., Fischer R., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. JClin Invest 2003, 112:1506-1520.
73. Gatto M., Zen M., Ghirardello A., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013, 12:523-536.
74. Borchers A.T., Leibushor N., Naguwa S.M., et al. Lupus nephritis: a critical review. Autoimmun Rev 2012, 12:174-194.
75. Ghirardello A., Villalta D., Morozzi G., et al. Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol 2011, 29:50-56.
76. Gutierrez-Adrianzen O.A., Koutouzov S., Mota R.M., et al. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. JRheumatol 2006, 33:1538-1544.
77. Rekvig O.P., Putterman C., Casu C., et al. Autoantibodies in lupus: culprits or passive bystanders?. Autoimmun Rev 2012, 11:596-603.
78. Pickering M.C., Botto M. Are anti-C1q antibodies different from other SLE autoantibodies?. Nat Rev Rheumatol 2010, 6:490-493.
79. Sinico R.A., Rimoldi L., Radice A., et al. Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 2009, 1173:47-51.
80. Atta A.M., Santiago M.B., Guerra F.G., et al. Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus. Int Arch Allergy Immunol 2010, 152:401-406.
81. Charles N., Hardwick D., Daugas E., et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010, 16:701-707.
82. McMurray R.W., May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum 2003, 48:2100-2110.
83. Li J., May W., McMurray R.W. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum 2005, 52:3701-3712.
84. Cooper G.S., Dooley M.A., Treadwell E.L., et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 2002, 46:1830-1839.
85. Ulff-Moller C.J., Jorgensen K.T., Pedersen B.V., et al. Reproductive factors and risk of systemic lupus erythematosus: nationwide cohort study in Denmark. JRheumatol 2009, 36:1903-1909.
86. Weetman A.P., Walport M.J. The association of autoimmune thyroiditis with systemic lupus erythematosus. Br J Rheumatol 1987, 26:359-361.
87. Gluck T., Oertel M., Reber T., et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous system axis. JRheumatol 2000, 27:903-910.
88. James J.A., Kaufman K.M., Farris A.D., et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. JClin Invest 1997, 100:3019-3026.
89. Lehmann P., Holzle E., Kind P., et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. JAm Acad Dermatol 1990, 22:181-187.
90. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. JExp Med 1994, 179:1317-1330.
91. Yung R., Powers D., Johnson K., et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. JClin Invest 1996, 97:2866-2871.
92. Parks C.G., Cooper G.S., Nylander-French L.A., et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 2002, 46:1840-1850.
93. Freemer M.M., King T.E., Criswell L.A. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 2006, 65:581-584.
94. Cooper G.S., Dooley M.A., Treadwell E.L., et al. Risk factors for development of systemiclupus erythematosus: allergies, infections, and family history. JClin Epidemiol 2002, 55:982-989.
95. Wang J., Kay A.B., Fletcher J., et al. Alcohol consumption is not protective for systemic lupus erythematosus. Ann Rheum Dis 2009, 68:345-348.
96. Tench C.M., McCurdie I., White P.D., et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000, 39:1249-1254.
97. Wang B., Gladman D.D., Urowitz M.B. Fatigue in lupus is not correlated with disease activity. JRheumatol 1998, 25:892-895.
98. Wolfe F., Petri M., Alarcon G.S., et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. JRheumatol 2009, 36:82-88.
99. Iaboni A., Ibanez D., Gladman D.D., et al. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. JRheumatol 2006, 33:2453-2457.
100. Zhou W.J., Yang C.D. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus 2009, 18:807-812.
101. Stahl N.I., Klippel J.H., Decker J.L. Fever in systemic lupus erythematosus. Am J Med 1979, 67:935-940.
102. Zandman-Goddard G., Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol 2003, 25:29-40.
103. van Vugt R.M., Derksen R.H., Kater L., et al. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998, 57:540-544.
104. Grossman J.M. Lupus arthritis. Best Pract Res Clin Rheumatol 2009, 23:495-506.
105. Cronin M.E. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1988, 14:99-116.
106. Tian X.P., Zhang X. Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 2010, 16:2971-2977.
107. Zheng W.J., Tian X.P., Li L., et al. Protein-losing enteropathy in systemic lupus erythematosus: analysis of the clinical features of fifteen patients. JClin Rheumatol 2007, 13:313-316.
108. Pardos-Gea J., Ordi-Ros J., Selva A., et al. Chronic intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus. Lupus 2005, 14:328-330.
109. Makol A., Petri M. Pancreatitis in systemic lupus erythematosus: frequency and associated factors - a review of the Hopkins Lupus Cohort. JRheumatol 2010, 37:341-345.
110. Quadrelli S.A., Alvarez C., Arce S.C., et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus 2009, 18:1053-1060.
111. Cheema G.S., Quismorio F.P. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000, 6:424-429.
112. Wiedemann H.P., Matthay R.A. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med 1989, 10:677-722.
113. Kim W.U., Kim S.I., Yoo W.H., et al. Adult respiratory distress syndrome in systemic lupus erythematosus: causes and prognostic factors: a single center, retrospective study. Lupus 1999, 8:552-557.
114. Badsha H., Teh C.L., Kong K.O., et al. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 2004, 33:414-421.
115. Weinrib L., Sharma O.P., Quismorio F.P. Along-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990, 20:48-56.
116. Karim M.Y., Miranda L.C., Tench C.M., et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 2002, 31:289-298.
117. Kamen D.L., Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 2010, 31:479-488.
118. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
119. Petri M., Perez-Gutthann S., Spence D., et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93:513-519.
120. Owlia M.B., Mostafavi Pour Manshadi S.M., Naderi N. Cardiac manifestations of rheumatological conditions: a narrative review. ISRN Rheumatol 2012, 2012:463620.
121. Frostegard J. SLE, atherosclerosis and cardiovascular disease. JIntern Med 2005, 257:485-495.
122. Chiewthanakul P., Sawanyawisuth K., Foocharoen C., et al. Clinical features and predictive factors in neuropsychiatric lupus. Asian Pac J Allergy Immunol 2012, 30:55-60.
123. Meszaros Z.S., Perl A., Faraone S.V. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. JClin Psychiatry 2012, 73:993-1001.
124. Hanly J.G., Fisk J.D., McCurdy G., et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. JRheumatol 2005, 32:1459-1466.
125. Mok C.C., Lau C.S., Wong R.W. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. JRheumatol 2001, 28:766-771.
126. Jallouli M., Frigui M., Marzouk S., et al. Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus. Lupus 2012, 21:682-687.
127. Hepburn A.L., Narat S., Mason J.C. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49:2243-2254.
128. Tarr T., Lakos G., Bhattoa H.P., et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol 2007, 32:131-137.
129. Nojima J., Kuratsune H., Suehisa E., et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001, 114:647-654.
130. Palejwala N.V., Walia H.S., Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis 2012, 2012:290898.
131. Frith P., Burge S.M., Millard P.R., et al. External ocular findings in lupus erythematosus: a clinical and immunopathological study. Br J Ophthalmol 1990, 74:163-167.
132. Lin Y.C., Wang A.G., Yen M.Y. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol 2009, 87:204-210.
133. Giorgi D., Balacco G.C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol 1999, 18:124-131.
134. Uva L., Miguel D., Pinheiro C., et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012, 2012:834291.
135. Lopez-Labady J., Villarroel-Dorrego M., Gonzalez N., et al. Oral manifestations of systemic and cutaneous lupus erythematosus in a Venezuelan population. JOral Pathol Med 2007, 36:524-527.
136. Nico M.M., Vilela M.A., Rivitti E.A., et al. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol 2008, 18:376-381.
137. Brennan M.T., Valerin M.A., Napenas J.J., et al. Oral manifestations of patients with lupus erythematosus. Dent Clin North Am 2005, 49:127-141. ix.
138. Yao Q., Altman R.D., Wang X. Systemic lupus erythematosus with Sjogren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. JClin Rheumatol 2012, 18:28-32.
139. Karjalainen T.K., Tomich C.E. Ahistopathologic study of oral mucosal lupus erythematosus. Oral Surg Oral Med Oral Pathol 1989, 67:547-554.
140. Crowson A.N., Magro C. The cutaneous pathology of lupus erythematosus: a review. JCutan Pathol 2001, 28:1-23.
141. Lourenco S.V., Nacagami S.M., Constantino Vilela M.A., et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of epithelial maturation. JCutan Pathol 2006, 33:657-662.
142. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
143. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
144. Petri M., Orbai A.M., Alarcon G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
145. Francis L., Perl A. Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother 2009, 10:1481-1494.
146. Bertsias G., Gordon C., Boumpas D.T. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future-the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 2008, 17:437-442.
147. Baker K.P., Edwards B.M., Main S.H., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
148. Navarra S.V., Guzman R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
149. Furie R., Petri M., Zamani O., et al. Aphase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.